Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 12;74(8):1277-1281.
doi: 10.1093/gerona/gly191.

Patient-Important Adverse Events of β-blockers in Frail Older Adults after Acute Myocardial Infarction

Affiliations

Patient-Important Adverse Events of β-blockers in Frail Older Adults after Acute Myocardial Infarction

Andrew R Zullo et al. J Gerontol A Biol Sci Med Sci. .

Abstract

Background: We evaluated the burden of adverse events caused by β-blocker use after acute myocardial infarction (AMI) in frail, older nursing home (NH) residents.

Methods: This retrospective cohort study used national Medicare claims linked to Minimum Data Set assessments. The study population was individuals aged ≥65 years who resided in a U.S. NH for ≥30 days, had a hospitalized AMI between May 2007 and March 2010, and returned to the NH. Exposure was new use of β-blockers versus nonuse post-AMI. Orthostasis, general hypotension, falls, dizziness, syncope, and breathlessness outcomes were measured over 90 days of follow-up. Odds ratios (ORs) with 95% confidence intervals (CIs) for outcomes were estimated using multinomial logistic regression models after 1:1 propensity score-matching of β-blocker users to nonusers.

Results: Among the 10,992 NH propensity score-matched residents with an AMI, the mean age was 84 years and 70.9% were female. β-blocker users were more likely than nonusers to be hospitalized for hypotension (OR = 1.20, 95% CI 1.03-1.39) or experience breathlessness (OR = 1.10, 95% CI 1.01-1.20) after AMI. With the exception of falls, other outcome estimates, though imprecise, were compatible with a potential elevated risk of orthostasis (OR = 1.14, 95% CI 0.96-1.35), syncope, (OR = 1.24, 95% CI 0.55-2.77), and dizziness (OR = 1.28, 95% CI 0.82-1.99) among β-blocker users.

Conclusions: Considered alongside prior evidence that β-blockers may worsen functional outcomes in NH residents with poor baseline functional and cognitive status, our results suggest that providers should exercise caution when prescribing for these vulnerable groups, balancing the mortality benefit against the potential for causing adverse events.

Keywords: Activities of daily living; Adrenergic beta-antagonists; Drug-related side effects and adverse reactions; Myocardial infarction; Nursing homes.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Amsterdam EA, Wenger NK, Brindis RG, et al. . AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:e344–426. doi:10.1161/CIR.0000000000000134 - DOI - PubMed
    1. O’Gara PT, Kushner FG, Ascheim DD, et al. . ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:529–555. doi:10.1161/CIR.0b013e3182742c84 - DOI - PubMed
    1. Willham K, Covinsky K, Widera E. Geriatrics literature 2016 year in review. J Am Geriatr Soc. 2017;65:2146–2150. doi:10.1111/jgs.15064 - DOI - PubMed
    1. Tjia J, Lapane K. Guideline-based prescribing in frail elderly patients. JAMA Intern Med. 2017;177:262–263. doi:10.1001/jamainternmed.2016.7714 - DOI - PubMed
    1. Steinman MA, Zullo AR, Lee Y, et al. . Association of β-Blockers with functional outcomes, death, and rehospitalization in older nursing home residents after acute myocardial infarction. JAMA Intern Med. 2017;177:254–262. doi:10.1001/jamainternmed.2016.7701 - DOI - PMC - PubMed

Publication types

Substances